Intention to Cease Coverage of Australian Clinical Labs

Australian Clinical Labs' strategy centers on capitalizing on the growing demand for diagnostic testing. Volume growth is underpinned by population growth, aging demographics, higher incidence of diseases, and wider adoption of preventative diagnostics to manage healthcare costs. These drivers are often greater in lower-density Australian states where ACL is largely based. In addition, the number of tests available is expanding. Increasing complexity of tests, such as veterinary and gene-based testing, is also resulting in average fee price increases. The majority of group revenue is earned from the public health Medicare system via bulk billing.